Cargando…

Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for leptomeningeal metastasis and successful treatment with osimertinib: A case report and literature review

Detalles Bibliográficos
Autores principales:	Sakurai, Takeo, Tuchida, Akimasa, Nishida, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749422/ https://www.ncbi.nlm.nih.gov/pubmed/33367120 http://dx.doi.org/10.1016/j.ensci.2020.100303

Ejemplares similares

Leptomeningeal Metastasis: The Role of Cerebrospinal Fluid Diagnostics
por: Bönig, Lena, et al.
Publicado: (2019)

Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis
por: Nie, Naifu, et al.
Publicado: (2022)

Diagnostic Value of CYFRA 21-1 in the Cerebrospinal Fluid for Leptomeningeal Metastasis
por: Zhang, Zhen, et al.
Publicado: (2017)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Prognostic significance of molecular characteristics of cerebrospinal fluid for non‐small cell lung cancer patients with leptomeningeal metastasis
por: Li, Ning, et al.
Publicado: (2019)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
por: Zhang, Milan, et al.
Publicado: (2021)

Cerebrospinal fluid metabolomic profiles can discriminate patients with leptomeningeal carcinomatosis from patients at high risk for leptomeningeal metastasis
por: Yoo, Byong Chul, et al.
Publicado: (2017)

Diagnostic Value of Cerebrospinal Fluid Level of Carcinoembryonic Antigen in Patients with Leptomeningeal Carcinomatous Metastasis
por: Kang, Sung Jin, et al.
Publicado: (2010)

Identification of Cerebrospinal Fluid MicroRNAs Associated With Leptomeningeal Metastasis From Lung Adenocarcinoma
por: Pan, Zhenyu, et al.
Publicado: (2020)

Experimental Assessment of Leptomeningeal Metastasis Diagnosis in Medulloblastoma Using Cerebrospinal Fluid Metabolomic Profiles
por: Im, Ji Hye, et al.
Publicado: (2021)

Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis.
por: Hovestadt, A., et al.
Publicado: (1990)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
por: Zajec, Marina, et al.
Publicado: (2020)

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
por: Naidoo, Jarushka, et al.
Publicado: (2021)

Deep Learning-Based Classification of Cancer Cell in Leptomeningeal Metastasis on Cytomorphologic Features of Cerebrospinal Fluid
por: Yu, Wenjin, et al.
Publicado: (2022)

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
por: Yang, James C.H., et al.
Publicado: (2020)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid
por: Liao, Pei-Ya, et al.
Publicado: (2022)

Mannan-binding lectin in cerebrospinal fluid: a leptomeningeal protein
por: Reiber, Hansotto, et al.
Publicado: (2012)

Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis
por: Kim, Hye Seon, et al.
Publicado: (2019)

Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
por: Xu, Haiyan, et al.
Publicado: (2021)

Cerebrospinal fluid protein levels are elevated 100 times in a Leptomeningeal metastasis patient: a case report and literature review
por: Wang, Shengnan, et al.
Publicado: (2023)

Sequencing of cerebrospinal fluid in non‐small‐cell lung cancer patients with leptomeningeal metastasis: A systematic review
por: Gao, Tianqi, et al.
Publicado: (2022)

Salvage therapy of osimertinib plus anlotinib in advanced lung adenocarcinoma with leptomeningeal metastasis: A case report
por: Wu, Kai, et al.
Publicado: (2022)

Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis
por: Le Rhun, Emilie, et al.
Publicado: (2012)

Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis
por: Wijetunga, N Ari, et al.
Publicado: (2021)

Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid
por: Juanes-Velasco, Pablo, et al.
Publicado: (2022)

Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid
por: White, Michael D., et al.
Publicado: (2021)

Cerebrospinal fluid cytology findings in a case of diffuse leptomeningeal glioneuronal tumour
por: Jensen, Melanie P., et al.
Publicado: (2022)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
por: Merkhofer, Cristina M., et al.
Publicado: (2021)

Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study
por: Mitsuya, Koichi, et al.
Publicado: (2019)

LPTO-07. CARCINOEMBRYONIC ANTIGEN OF CEREBROSPINAL FLUID PREDICT PROGNOSIS OF LEPTOMENINGEAL METASTASIS FROM NON-SMALL CELL LUNG CANCER
por: Zhen, Junjie, et al.
Publicado: (2019)

MBRS-56. RE-EVALUATION OF LEPTOMENINGEAL METASTASIS IN MEDULLOBLASTOMA WITH MAGNETIC RESONANCE IMAGING, RELATED SYMPTOMS AND CEREBROSPINAL FLUID METABOLOMIC PROFILES
por: Im, Ji Hye, et al.
Publicado: (2020)

Exploratory Profiling of Extracellular MicroRNAs in Cerebrospinal Fluid Comparing Leptomeningeal Metastasis with Other Central Nervous System Tumor Statuses
por: Im, Ji Hye, et al.
Publicado: (2021)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
por: Yi, Yali, et al.
Publicado: (2022)

Diagnostic and prognostic values of cerebrospinal fluid CYFRA 21-1 in patients with leptomeningeal carcinomatosis
por: Hyun, Jae-Won, et al.
Publicado: (2017)

Medulloblastoma uses GABA transaminase to survive in the cerebrospinal fluid microenvironment and promote leptomeningeal dissemination
por: Martirosian, Vahan, et al.
Publicado: (2021)

Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer
por: Chen, Xin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0brht7u7kmnlrr6kii5o7sveq0